Pharmainitiative Bayern Calls for AMNOG 2.0 Reform

Pharmainitiative Bayern, an initiative focused on the pharmaceutical sector, has released a position paper calling for a significant overhaul of Germany's drug assessment and pricing system, known as AMNOG (Arzneimittelmarktneuordnungsgesetz). The proposed reform, termed "AMNOG 2.0," aims to facilitate faster patient access to medical innovations, especially advanced therapy medicinal products (ATMPs) and treatments for rare diseases.

The current AMNOG framework, established in 2011, evaluates the additional benefit of new drugs to determine pricing and market access. However, Pharmainitiative Bayern argues that the system has structural weaknesses that hinder the assessment of ATMPs and orphan drugs. These highly innovative therapies, often offering curative potential for severe or previously untreatable conditions, may not receive adequate evaluation under existing methodologies.

The initiative highlights that standard assessment methods, such as randomized controlled trials (RCTs) and comparisons with established treatments, are often not feasible or appropriate for rare diseases and ATMPs. This is due to small patient populations, making statistically significant RCTs challenging, and ethical considerations that preclude placebo-controlled trials in life-threatening conditions.

"We need adapted assessment logics for orphan drugs and ATMPs," stated Dr. Andreas Heigl, Head of Health Policy at Servier and a co-author of the paper. He emphasized that current standards, developed for earlier generations of medicines, do not fully capture the transformative nature of these new therapies and create barriers to their adoption.

Pharmainitiative Bayern proposes incorporating a formal procedure within AMNOG to recognize "special therapeutic situations." This would allow for flexible assessment criteria in cases where traditional trial designs are impractical. The ultimate aim is to ensure that the evaluation of these groundbreaking treatments accurately reflects their medical value and accelerates their availability to patients in need.